The FDA has granted breakthrough device designation to SightGlass Vision’s diffusion optics technology spectacle lenses, which are designed to slow myopia progression in children.
“Recent studies illustrate that about half of U.S. children are myopic, yet most are not receiving treatments proven to slow myopia progression,” Andrew Sedgwick, SightGlass Vision’s CEO, said in a company press release. “We are enthusiastic about more closely collaborating with the FDA as we pursue U.S. market clearance.”
According to the release, the company’s diffusion